Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 4, 2011, Pages 790-795

  Govindan, Ramaswamy ^a,b   Morgensztern, Daniel ^a,b   Kommor, Michael D ^c   Herbst, Roy S ^d   Schaefer, Paul ^e   Gandhi, Jitendra ^f   Saito, Kaku ^g   Zergebel, Christopher ^g   Schiller, Joan ^h  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

^c University of Texas MD Anderson Cancer Center ^*  (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Toledo Community Hospital Oncology Program   (United States)

^f Associates in Oncology and Hematology   (United States)

^g Taiho Pharma USA Inc   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

NSCLC; Phase II; S1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 79953026444     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182103b51     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer JClin 2009;59:225-249.
2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. JClin Oncol 2006;24:4539-4544. (Pubitemid 46630948)
3. Morgensztern D, Ng S, Gao F, et al. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database Survey. J Thorac Oncol 2010;5:29-33.
4. Pignon J, Tribodet H, Scagliotti G, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3559.
5. Fossella F, DeVore R, Kerr R, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362. (Pubitemid 30415821)
6. Shepherd F, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103. (Pubitemid 30324363)
7. Hanna N, Shepherd F, Fossella F, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22: 1589-1597. (Pubitemid 41079796)
8. Shepherd F, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132. (Pubitemid 41058344)
9. Heidelberger C, Chaudhuri N, Danneberg P, et al. Fluorinated pyrimi-dines, a new class of tumour-inhibitory compounds. Nature 1957;179: 663-666.
10. Langer C The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer. Lung Cancer 2001;34:297-303. (Pubitemid 33010806)
11. Fukushima M, Morita M, Ikeda K, et al. Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in pa-tients with solid tumors. Int J Mol Med 2003;12:839-844.
12. Fukui Y, Oka T, Nagayama S, et al. Thymidylate synthase, dihydropy-rimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med 2008;22:709-716.
13. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002;7: 288-323. (Pubitemid 34919955)
14. Lamont E, Schilsky R. The oral fluoropyrimidines in cancer chemother-apy. Clin Cancer Res 1999;5:2289-2296.
15. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-4009. (Pubitemid 23267702)
16. Cohen S, Leichman C, Yeslow G, et al. Phase I and pharmacokinetic study of once daily oral administration ofS-1 in patients with advanced cancer. Clin Cancer Res 2002;8:2116-2122. (Pubitemid 34753581)
17. van Groeningen C, Peters G, Schornagel J, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000;18:2772-2779. (Pubitemid 30463561)
18. Chu Q, Hammond L, Schwartz G, et al. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res 2004;10:4913-4921. (Pubitemid 39099764)
19. Hoff P, Saad E, Ajani J, et al. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 2003;9:134-142. (Pubitemid 36109725)
20. Hirata K, Horikoshi N, Aba K, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999;5:2000-2005. (Pubitemid 29399250)
21. Available at: http://www.clinicaltrials.gov/ct2/show/study/NCT00227552. Accessed August 20, 2010.
22. Kawahara M, Furuse K, Segawa Y, et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001;85:939-943. (Pubitemid 33015993)
23. Ichinose Y, Yoshimori K, Sakai H, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 2004;10:7860-7864. (Pubitemid 39587524)
24. Kaira K, Sunaga N, Yanagitani N, et al. Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2010;68:253-257.
25. Okamoto I, Nishimura T, Miyazaki M, et al. Phase II study of combi-nation therapy with S-1 and irinotecan for advanced non-small cell lung cancer: West Japan Thoracic Oncology Group 3505. Clin Cancer Res 2008;14:5250-5254.
26. Takiguchi Y, Tada Y, Gemma A, et al. Phase I/II study ofdocetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer. Lung Cancer 2010;68:409-414.
27. Nokihara H, Nagai S, Kato T, et al. A phase II study of S-1 in non-small cell lung cancer (NSCLC) patients previously treated with a platinum-based regimen. J Thorac Oncol 2007;2(Suppl 4):S687.
28. Zhu AX, Clark JW, Ryan DP, et al. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother Pharmacol 2007;59:285-293. (Pubitemid 46025515)
29. Seto T, Morita S, Ando M, et al. S-1 plus carboplatin has become one of the standard regimens for advanced non-small-cell lung cancer: results of a randomized phase III study conducted by the West Japan Oncology Group (WJTOG 3605). Ann Oncol 2010;21(Suppl 8):viii122-viii161:374PD.
30. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemother-apy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
31. Haller DG, Cassidy J. Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008;26: 2118-2123.
32. Ichikawa W, Sasaki Y. Challenges in predicting the clinical outcome in S-1-based chemotherapy for gastric cancer patients. Int J Clin Oncol 2008;13:206-211. (Pubitemid 351871897)
33. Naito S, Eto M, Shinohara N, et al. Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2010;28:5022-5029.